Lidocaine transdermal patch - Endo Pharmaceuticals
Alternative Names: Lidoderm; VersatisLatest Information Update: 04 Jun 2024
At a glance
- Originator Endo Pharmaceuticals; Teikoku Pharma USA
- Developer Endo Pharmaceuticals; Grunenthal; Teikoku Pharma USA
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postherpetic neuralgia
- Discontinued Back pain; Musculoskeletal pain; Neuropathic pain
Most Recent Events
- 08 May 2024 Registered for Postherpetic neuralgia in China (Transdermal)
- 07 Sep 2022 Discontinued - Phase-III for Neuropathic pain in Austria, Italy, Spain, United Kingdom, France, Denmark, Brazil, Belgium (Transdermal)
- 22 Jul 2022 No development reported - Phase-III for Neuropathic pain in Austria, Belgium, Brazil, Denmark, France, United Kingdom, Spain, Italy (Transdermal)